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Abstract: This paper provides an overview of the baseline data collected in the nationwide 
Danish Centre for Strategic Research in Type 2 Diabetes (DD2) project. The paper presents 
descriptive data from the first 580 patients enrolled in the DD2. The DD2 database will 
 contain detailed interview data, clinical examination data, and urine and blood samples from 
up to 10,000 patients newly diagnosed with type 2 diabetes each year, collected from general 
 practitioners and hospital outpatient clinics in all of Denmark. Of the first DD2 patients enrolled, 
blood and urine samples have been obtained from 97%. The median age of the first 580 patients 
was 59 years and 322 (56%) were men. Median weight gain from age 20 to maximum lifetime 
weight was 29 kg for men and 31 kg for women, and 364 patients (63%) did not currently par-
ticipate in regular sports activities. Two hundred and ninety two patients (50%) had a known 
family history of  diabetes. Two hundred fifty (43%) of the 580 DD2 patients have also been 
enrolled in the  Danish Diabetes Database for Adults from which additional clinical data can be 
obtained. Among these 250 patients (154 of whom were men, 96 women), 75 (49%) men were 
currently obese, and 63 (41%) were overweight, whereas 62 (65%) women were obese, and 
another 21 (22%) were overweight. Twenty-nine patients (12%) received insulin, 164 patients 
(66%) received oral antidiabetics only, and 57 (23%) received no antidiabetic treatment. Glycemic 
regulation was modest (the glycosylated hemoglobin A of 46% was $7.5%). Two thirds of the 
patients received antihypertensive and hypolipidemic treatment. Self-reported daily tobacco 
smoking (23%) and alcohol overuse (6%) seemed comparable to occurrence in the general 
Danish population. One quarter of the patients with newly diagnosed diabetes had a history of 
hospital-diagnosed comorbidity at baseline as included in the Charlson comorbidity index, in 
particular prior myocardial infarction (5%), cerebrovascular disease (5%), peripheral vascular 
disease (4%), chronic pulmonary disease (6%), and previous solid cancer (6%). In the future, 
the DD2 database represents a valuable source for outcome studies in type 2 diabetes.
Keywords: type 2 diabetes, epidemiological methods, registries, prognosis
Introduction
Denmark has 5.6 million mixed rural and urban inhabitants and is a welfare state, with 
tax-financed universal access to health services.1 The Danish National Health Service 
guarantees unfettered access to primary care and public hospitals, which are free at point 
of delivery, and provides partial reimbursement for prescribed medications. Except 
for emergencies, patients’ initial contact with the health care system is through their 
general practitioners (GPs), who provide referrals to hospitals and privately practicing 
specialists as necessary.2
In this setting, the nationwide Danish Centre for Strategic Research in Type 2 
 Diabetes (DD2) project started testing patient enrollment in late 2010. DD2 will be 
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one of the world’s largest prospectively designed diabetes 
research projects, and this is the first time a nationwide 
comprehensive type 2 diabetes research project of this 
kind has been conducted in Denmark. DD2 aims to enroll 
10,000 patients per year when fully implemented nationwide, 
 corresponding to approximately half of all patients with 
newly diagnosed type 2 diabetes in Denmark. The project 
will continue until at least 50,000 patients with type 2 dia-
betes have been enrolled. The DD2 database will contain 
detailed interview and clinical examination data from these 
patients, including background and lifestyle factors, tobacco 
and alcohol intake, physical activity, family history of diabe-
tes, anthropometric and other clinical measurements, blood 
pressure and lipids, glycemic regulation, and treatment of 
diabetes. Many of these variables will be obtained by linking 
with current databases. All patients are registered by their 
unique personal identifier, the civil personal registration 
number (CPR number). This enables the DD2 cohort to be 
linked to a wide range of Danish medical and administrative 
registries, with detailed historical and prospective data on 
use of medications, hospital contacts and diagnoses,  surgical 
procedures, dialysis, socioeconomic prognosis, and total 
and cause-specific mortality, as described in more detail 
elsewhere.3
The aim of the current paper is to present a short overview 
of the baseline data collected in the DD2 database. The paper 
includes a presentation of interview and clinical examination 
data from the first 580 patients enrolled in the DD2.
Baseline data: what is recorded  
in the DD2 database?
The DD2 project enrolls patients newly diagnosed with 
type 2 diabetes from GPs and hospital outpatient clinics 
throughout Denmark. The implementation and logistics 
of the DD2 project are described in detail elsewhere.4 
In brief, an online questionnaire is filled out by GPs or 
hospital physicians for each DD2 patient at the time of 
enrollment, and blood and urine samples are collected. 
Data are electronically transferred to the DD2 database 
managed by the Department of Clinical Epidemiology at 
Aarhus University Hospital. To make enrolling a large 
number of patients in the DD2 fast and simple, relatively 
few interview and clinical data are collected, and additional 
data are extracted from Danish population-based databases. 
Thus, the DD2 database is regularly updated through links 
with additional clinical data from the Danish Diabetes 
Database for Adults (DDDA), as described in detail 
elsewhere.2
Hospital outpatient clinics and GPs started enrolling 
DD2 patients and transferring data to the DD2 database 
in November 2010. Registration of patients and sample 
 collection in the DD2 database were approved by the National 
Committee on Health Research Ehitics (Denmark) (record 
number S-20100082) and the Danish Data Protection Agency 
(record number 2008-58-0035). Patients volunteer to partici-
pate in the DD2 project and have to sign a written informed 
 consent  document, after first receiving detailed oral and 
written information approved by the National Committee 
on Health Research Ethics. (Denmark).
Data recorded in the DD2 database include each patient’s 
identification number (CPR number), interview date, and 
detailed interview and clinical examination data. Blood and 
urine samples are obtained from each patient, either on the day 
of the interview or a later occasion, as described in detail by 
Nielsen et al.4 The DD2 online registration form is also described 
by Nielsen et al.4 Collected variables inputted directly in the 
DD2 database include hip–waist ratio, body weight at 20 years 
and maximum weight, alcohol intake, physical activity, family 
history of diabetes, and resting heart rate. Variables merged from 
the DDDA include date of first type 2 diabetes diagnosis, tobacco 
smoking, body mass index (BMI), blood pressure, glycosylated 
hemoglobin A (HbA
1c
), albuminuria, plasma lipids, antidiabetic 
treatment, antihypertensive treatment including angiotensin-
converting enzyme (ACE) inhibitors, hypolipidemic treatment, 
and examination of presence of diabetic foot and eye disease. 
Thus, up to 90 administrative and clinical variables are registered 
for each patient with type 2 diabetes.
Linking with the Danish National Registry of Patients5 
at baseline makes it possible to obtain a complete hospital 
 contact history since 1977 for each participant before the date 
of enrollment. We obtained information on participants’ major 
chronic diseases, defined as those included in the Charlson 
comorbidity index:6 myocardial infarction, congestive heart 
failure, peripheral vascular disease, cerebrovascular disease, 
dementia, chronic pulmonary disease, connective tissue 
disease, ulcer disease, liver disease, diabetes, hemiplegia, 
renal disease, cancer, and acquired immune deficiency 
syndrome. Based on hospital diagnosis codes for these 
conditions,7 we computed a Charlson comorbidity index 
score for each person,8 defining three comorbidity levels as 
low (score of 0), medium (1–2), and high (3+).
Data on the first 580 patients 
enrolled
Table 1 shows characteristics of the first 580 patients 
who have been enrolled and had interview and clinical 





Clinical Epidemiology 2012:4 (Suppl 1)
Table 1 Characteristics of the first 580 patients with newly 
diagnosed type 2 diabetes enrolled in the Danish Centre for 
Strategic Research in Type 2 Diabetes (DD2) project
Variable Patients with  
type 2 diabetes
Persons enrolled in DD2, n (%) N = 580 (100%)
Age, median (quartiles), years 59 (51–64)
Age range, years 24–83
gender, n (%)
 Male 322 (56)
 Female 258 (44)
Patient fasting at time of enrollment,a n (%)
 Yes 477 (82)
 No 89 (15)
 Missing information 14 (2)
Resting heart rate, median (quartiles) 70 (62–76)
Waist-hip ratio in men, median (quartiles) 1.01 (0.97–1.05)
Waist-hip ratio in women, median (quartiles) 0.91 (0.88–0.96)
Weight gain in men
Weight at age 20 years, median (quartiles), kg 76 (70–85)
 Don’t know weight at 20 years, n (%) 51 (16)
Maximum lifetime weight, median (quartiles), kg 106 (92–120)
 Don’t know maximum lifetime weight, n (%) 2 (1)
Weight gain since age 20, median (quartiles), kg 29 (18–41)
Weight gain in women
Weight at age 20 years, median (quartiles), kg 59 (52–69)
 Don’t know weight at 20 years, n (%) 42 (16)
Maximum lifetime weight, median (quartiles), kg 94 (80–110)
 Don’t know maximum lifetime weight, n (%) 4 (2)
Weight gain since age 20, median (quartiles), kg 31 (20–41)
Alcohol use, n (%)
 Maximum 14/21 drinks/weekb for women/men 544 (94)
 More than 14/21 drinks/week for women/men 36 (6)
Days per week with 30+ minutes of physical activity
 0 days 95 (16)
 1 day 40 (7)
 2 days 78 (13)
 3 days 76 (13)
 4 days 52 (9)
 5 days 57 (10)
 6 days 27 (5)
 7 days 155 (27)
Regular sports activities, n (%)
 Yes 216 (37)
 No 364 (63)
Level of physical activity during the last year, n (%)
  Hard physical training and competitive sports 
several times a week
4 (1)
  Leisure sports, heavy garden work or similar at  
least 4 hours per week
109 (19)
  Walking, cycling or other light exercise at least  
4 hours per week
364 (63)
  I read, watch television, or have other sedentary 
activity
103 (18)
Family history of diabetes, n (%)
 Yes 292 (50)
 No 227 (39)
 Don’t know 61 (11)
Notes: aBlood and urine samples are obtained either immediately at the interview 
or at a later occasion; bmaximum safe amount recommended in Denmark at the time 
of DD2 study start.
examination data transferred directly to the DD2 database by 
October 31, 2011. The median age of the study cohort was 
59 years (interquartile range 51–64 years), and 322 (56%) 
were men (Table 1). Eighty-two percent of the patients were 
fasting when they arrived for the interview and enrollment. 
Blood and urine samples have been obtained from 97% of 
the patients and are stored at the DD2 biobank (data not 
shown; see Christensen et al9). The maximum lifetime weight 
reached among study participants was a median of 100 kg 
(interquartile range 86–116 kg, maximum 250 kg), while 
weight at 20 years of age was 70 kg median (interquartile 
range 60–80 kg, maximum 170 kg), corresponding to a 
median weight gain from age 20 to maximum lifetime weight 
of 29 kg for men and 31 kg for women (Table 1). A number 
of 364 patients (63%) did no regular sports activities, and 
292 (50%) had a known family history of diabetes. Thirty-six 
patients (6%) reported having a total weekly alcohol intake 
in excess of the maximum safe amount recommended in 
Denmark at the time of DD2 study start (.14 drinks/week 
for women, .21 drinks/week for men) (Table 1).
Table 2 shows the history of hospital-diagnosed comor-
bidity at baseline among the 580 DD2 participants with 
newly diagnosed type 2 diabetes, ascertained by linking 
with the Danish National Registry of Patients. One quarter 
of the patients had comorbidities included in the Charlson 
comorbidity index before the date of enrollment.  Prevalent 
comorbidities were prior myocardial infarction (5%), 
 cerebrovascular disease (5%), peripheral vascular disease 
(4%), chronic pulmonary disease (6%), and previous solid 
cancer (6%) (Table 2).
The 580 patients were linked to the DDDA at the 
beginning of December 2011 to collect additional diabetes 
data. Two hundred fifty (43%) DD2 patients were registered 
in the DDDA (Table 3). The reasons for delayed data patient 
entry in the DDDA have been described below and  elsewhere.2 
As seen in Table 3, 58 (23%) were current daily smokers, 
and 93 (37%) were former smokers. Very few patients had a 
BMI within the normal range at enrollment in the DDDA: 75 
(49%) out of 154 men were currently obese, and 63 (41%) 
were overweight; whereas 62 (65%) of 96 women were 
obese, and another 21 (22%) were overweight. One hun-
dred sixteen (46%) patients had a median HbA
1c
 of 7.5% or 
more, and 36 (14%) of all patients had an albumin–creatinin 
ratio of 30 mg/g or more (the ratio was missing for 23% of 
patients). Patients received antidiabetic treatment in 77% of 
the cases: 29 patients (12%) received insulin, and 164 patients 
(66%) received oral antidiabetics only. Median systolic/dia-
stolic blood pressure was 130/81 mmHg, and median total 
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cholesterol was 4.4 (interquartile range 3.7–5.1) mmol/L. 
One hundred and fifty-six patients (62%) received antihy-
pertensive treatment, and 160 (64%) received hypolipidemic 
agents.
Data quality
When evaluating the overall quality of data for the enrolled 
DD2 patients, it is important to consider whether all data 
are recorded (no missing data) and whether the informa-
tion recorded in the database is correct. Information in 
the  database is entered by physicians and transferred 
electronically from the participating centers4 directly from 
the online questionnaire on the DD2 homepage (http://www.
dd2.nu) with theoretically minimal risk of data loss. The data 
quality is confirmed with automatic validation at data entry, 
for example, invalid/“false” CPR numbers are not accepted. 
To improve data quality, all variables must be filled in the 
questionnaire; however, a few variables have a “don’t know” 
category, as seen in Table 1. We found that data completeness 
was 100% for demographic variables and for most clinical 
characteristics (eg, anthropometric measurements, heart rate, 
Table 3 Characteristics of 250 patients enrolled in the nationwide 
Danish Centre for Strategic Research in type 2 Diabetes (DD2) 
project who are currently registered in the Danish Diabetes 
Database for Adults
Variable Patients with 
type 2 diabetes
N (%) participants in DD2 who currently are 
registered in the Danish Diabetes Database  
for Adults
250 (43)
Tobacco smoking, n (%)
 Never smoker 89 (36)
 Former smoker 93 (37)
 Current smoker, daily 58 (23)
 Current smoker, occasionally 4 (2)
 Smoking status listed unknown 6 (2)
Height and weight in men (n = 154)
Height, median (quartiles), cm 178 (174–184)
 Height missing, n (%) 5 (3)
Current weight, median (quartiles), kg 96 (86–109)
 Weight missing, n (%) 2 (1)
Current BMI, n (%)
 ,18.5 kg/m2 0 (0)
 18.5–24.9 kg/m2 11 (7)
 25–29.9 kg/m2 63 (41)
 30+ kg/m2 75 (49)
 BMI missing 7 (2.8)
Height and weight in women (n = 96)
Height, median (quartiles), cm 165 (160–170)
 Height missing, n (%) 2 (2)
Current weight, median (quartiles), kg 91 (78–102)
 Weight missing, n (%) 0 (0)
Current BMI, n (%)
 ,18.5 kg/m2 1 (1)
 18.5–24.9 kg/m2 10 (10)
 25–29.9 kg/m2 21 (22)
 30+ kg/m2 62 (65)
 BMI missing 2 (2)
HbA1c, n (%)
 ,7.5% 133 (53)
 $7.5% 116 (46)
 HbA1c missing 1 (0.4)
Albuminuria, n (%)
 Albumin–creatinin ratio , 30 mg/g 156 (62)
 Albumin–creatinin ratio $ 30 mg/g 36 (14)
 Albumin excretion $ 30 mg/day 1 (0.4)
 Albuminuria listed “unknown” 57 (23)
Blood pressure, median (quartiles), mmHg
 Systolic 130 (122–144)
 Diastolic 81 (75–90)
Lipids, median (quartiles), mmol/L
 Total-cholesterol 4.4 (3.7–5.1)
 HDL-cholesterol 1.2 (1.0–1.4)
 LDL-cholesterol 2,4 (1.9–3.1)
 Triglycerides 1.7 (1.2–2.5)
Antidiabetic treatment, n (%)
 Insulin only 9 (4)
 Insulin and oral 20 (8)
 Oral 164 (66)
(Continued)
Table 2 Hospital-diagnosed comorbidity at baseline among 
580 patients with newly diagnosed type 2 diabetes, ascertained by 
linkage with the Danish National Registry of Patients
N (%) participants in DD2 who can  
currently be linked to the Danish  




Comorbidities at baseline, n (%)a
 Prior myocardial infarction 28 (4.8)
 Congestive heart failure 7 (1.2)
 Peripheral vascular disease 22 (3.8)
 Cerebrovascular disease 31 (5.3)
 Dementia 0 (0.0)
 Chronic pulmonary disease 36 (6.2)
 Connective tissue disease 5 (0.9)
 Peptic ulcer disease 8 (1.4)
 Mild liver disease 7 (1.2)
 Hemiplegia 1 (0.2)
 Moderate to severe renal disease 7 (1.2)
 Solid cancer 32 (5.5)
 Leukemia 1 (0.2)
 Lymphoma 1 (0.2)
 Moderate to severe liver disease 1 (0.2)
 Metastatic solid cancer 5 (0.9)
 AIDS 2 (0.3)
Charlson comorbidity index score, n (%)b
 Low (0) 434 (74.8)
 Medium (1–2) 119 (20.5)
 High ($3) 27 (4.7)
Notes: aComorbidities included in the Charlson comorbidity index, except diabetes; 
bfor the calculation of the Charlson index score levels, see text.
Abbreviations: AIDS, acquired immune deficiency syndrome; DD2, Danish Centre 
for Strategic Research in Type 2 Diabetes.
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Table 3 (Continued)
Variable Patients with 
type 2 diabetes
 None 57 (23)
 Insulin pump, n (% of insulin treated) 0 (0)
Antihypertensive treatment, n (%) 156 (62)
ACE-inhibitor or ATII-antagonist treatment, n (%) 121 (48)
Hypolipidemic treatment, n (%) 160 (64)
Eye screening completed, n (%) 147 (59)
Foot examination completed, n (%) 232 (93)
Abbreviations: ACE, angiotensin-converting enzyme; ATII, angiotensin II; BMI, body 
mass index; HbA1c, glycosylated hemoglobin A; HDL, high-density lipoprotein; 
LDL, low-density lipoprotein.
physical activity, or alcohol use). The largest  proportion 
of “don’t know” responses was encountered for weight at 
20 years of age (16% reported “don’t know”) and family 
history of diabetes (11% reported “don’t know”). Hospital 
comorbidity history in Denmark since 1977 is complete, 
since all Danish hospitals report diagnoses to the Danish 
National Registry of Patients.5 We did not systematically 
validate the entered data in this report; this will be possible 
through future research projects, random spot checks, and 
linking to independent national registries using the CPR 
numbers, for example, to the Nationwide Prescription 
Database.10 The impact of missing or incorrectly measured 
data in the DD2 depends on the research  question and study 
design. Missing data (eg, on family history of diabetes or 
overweight at age 20) hamper studies on the prevalence 
of these conditions but do not necessarily hamper analytic 
 epidemiological studies if the measurement errors are 
unrelated to other study variables.
We found that only 43% of the first 580 patients in the 
DD2 database were also enrolled in the DDDA database 
(Table 2) at present and could have their DD2 data enriched 
by linking to the DDDA. This is probably related to 
delayed DDDA enrollment. The DDDA focuses on clinical 
performance measures during the last year among persons 
with known (prevalent) type 2 diabetes.2 Thus, it is possible 
but not mandatory for clinics and physicians to report newly 
diagnosed diabetes patients in the DDDA database at the time 
of first contact and it is therefore likely that while some clinics 
report their newly diagnosed diabetes patients immediately, 
others do not. This presumption is supported by the fact 
that the 250 DD2 patients who had available DDDA data 
were reported from relatively few hospital diabetes clinics, 
compared with the number of clinics that are known to 
regularly report diabetes patients to the DDDA (not shown). 
We therefore expect the proportion of DD2 patients who 
have supplementary data available in the DDDA to increase 
substantially in the future. Among patients registered in the 
DDDA, completeness of data is also very high – for example, 
more than 95% for smoking, BMI, HbA
1c
, blood pressure, 
and all blood tests and medications, except for albuminuria 
(for which 23% is missing).
The current patient sample was predominantly reported 
from hospital diabetes clinics and may include patients with 
more severe than average newly diagnosed type 2 diabetes. 
Representativeness is likely to increase when more GPs begin 
to include diabetes patients in the DD2.4
Conclusion
We have presented data for the first 580 patients enrolled in 
the DD2. Up to 90 interview and clinical examination data 
variables are registered for each participant. The median 
age was 59 years, almost all patients were overweight or 
obese, and half of the participants had a family history of 
diabetes. Two thirds received oral antidiabetics only and 
12% received insulin, with modest glycemic regulation. 
Two thirds of patients received antihypertensive and hypo-
lipidemic treatment. One quarter had previous hospital-
diagnosed comorbidity, cardiovascular disease in particular. 
We found that completeness of primary DD2 variables was 
very high, except for weight at age 20 and family history of 
diabetes, which must be improved. Another limitation was 
the fact that less than half of the DD2 participants were cur-
rently recorded in the DDDA database to have their clinical 
data enriched. We believe that future updated data links will 
substantially improve completeness.
The DD2 database will become a very valuable source 
for large clinical epidemiological research and outcome 
studies in type 2 diabetes. The database provides ongoing 
longitudinal registration of a wealth of data on patients 
with diabetes not routinely available in medical registries. 
Linking other unique Danish population-based registries 
with the DD2 database will make it possible to ascertain 
complete data on these patients’ previous and future use 
of medications, hospital contacts and diagnoses, surgical 
procedures, dialysis, socioeconomic prognosis, and total and 
cause-specific mortality.
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